Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Nasdaq Biotechnology Ishares ETF (IBB)

Nasdaq Biotechnology Ishares ETF (IBB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fund Basics

See More
  • Fund Family BlackRock iShares
  • Assets Under Management 6,702,864,800
  • Shares Outstanding, K 50,500
  • 60-Month Beta 0.84
  • Price/Earnings ttm 15.68
  • Annual Dividend & Yield 0.39 (0.29%)
  • Most Recent Dividend 0.062 on 12/17/24
  • Management Fee 0.44%
  • Sectors:

    ETFs - Biotech

Options Overview Details

View History
  • Implied Volatility 21.25% ( -3.35%)
  • Historical Volatility 23.54%
  • IV Percentile 88%
  • IV Rank 34.70%
  • IV High 33.78% on 08/05/24
  • IV Low 14.59% on 07/10/24
  • Put/Call Vol Ratio 1.88
  • Today's Volume 7,678
  • Volume Avg (30-Day) 2,720
  • Put/Call OI Ratio 1.43
  • Today's Open Interest 165,133
  • Open Int (30-Day) 163,651

Price Performance

See More
Period Period Low Period High Performance
1-Month
129.61 +2.41%
on 12/19/24
142.84 -7.08%
on 12/09/24
-2.11 (-1.56%)
since 11/20/24
3-Month
129.61 +2.41%
on 12/19/24
150.04 -11.54%
on 11/11/24
-15.25 (-10.31%)
since 09/20/24
52-Week
123.60 +7.39%
on 04/19/24
150.57 -11.85%
on 09/19/24
+3.85 (+2.99%)
since 12/20/23

Most Recent Stories

More News
Altimmune’s Nasdaq Biotech Index Addition Fuels Retail Enthusiasm, Stock Rebounds

The NBI serves as the basis for the iShares NASDAQ Biotechnology Index Fund and is reevaluated annually.

IBB : 132.73 (+1.16%)
ALT : 8.25 (+0.86%)
Novavax Nabs $50M From First Sanofi Partnership Milestone: Retail Optimism Climbs

This milestone marks the first achievement since the partnership began in May, with the potential for Novavax to earn up to $300 million in additional milestones.

IBB : 132.73 (+1.16%)
VTI : 293.28 (+1.14%)
NVAX : 8.70 (+0.23%)
IWM : 221.92 (+0.94%)
Amgen Stock Slips After More Analyst Criticism On Weight-Loss Drug Data: Retail Eyes ‘Great Buying Opportunity’

An RBC Capital analyst noted that while MariTide’s efficacy aligns with the brokerage’s expectations, its tolerability and long-term dosing regimen leave room for improvement.

IBB : 132.73 (+1.16%)
AMGN : 263.38 (+0.84%)
SPY : 591.15 (+1.20%)
Amgen Stock Sinks On Modest Obesity Drug Results, But Retail Sentiment Remains Steady

Amgen’s weight-loss drug candidate MariTide is meant to be administered subcutaneously monthly or less frequently in obese or overweight patients without Type 2 diabetes.

IBB : 132.73 (+1.16%)
AMGN : 263.38 (+0.84%)
SPY : 591.15 (+1.20%)
XBI : 91.28 (+1.64%)
Eli Lilly, Novo Nordisk Shares Climb Premarket As Biden Administration Mulls Medicare, Medicaid Covering For Obesity Drugs: Retail Unmoved

he new proposal would expand access to medications for obesity, and help an estimated 3.4 million Americans with Medicare.

NVO : 85.00 (-17.83%)
OZEM : 24.45 (-2.94%)
LLY : 767.76 (+1.35%)
IBB : 132.73 (+1.16%)
XBI : 91.28 (+1.64%)
Replimune Stock Hits 1-Year High In After-hours As Small-Cap Biotech Files For FDA Approval Of Skin Cancer Combo Therapy: Retail Upbeat

Replimune’s lead asset RP1 is based on a proprietary new strain of Herpes simplex virus engineered to maximize tumor killing potency.

IBB : 132.73 (+1.16%)
REPL : 12.49 (+4.00%)
XBI : 91.28 (+1.64%)
Are Wall Street Analysts Predicting Bio-Techne Stock Will Climb or Sink?

Bio-Techne has underperformed the broader market over the past year, yet analysts remain bullish on the stock’s prospects.

TECH : 73.17 (+2.49%)
$SPX : 5,930.85 (+1.09%)
IBB : 132.73 (+1.16%)
Is Biotech’s Bull Run Over? Examining Election Impacts

The biotech sector's breakout attempt post-election reversed sharply, with ETFs like IBB and XBI falling and invalidating the long-term bullish setup.

IBB : 132.73 (+1.16%)
NVAX : 8.70 (+0.23%)
MRNA : 39.39 (-0.43%)
XBI : 91.28 (+1.64%)
PFE : 26.36 (+2.29%)
5 Stocks Retail Investors Are Most Bullish On At Mid-Day

Retailers went overboard about a couple of biotech stocks and a MedTech name, among others on Wednesday.

FBRX : 19.34 (+3.64%)
QSI : 1.3000 (+0.78%)
DUOT : 5.70 (+26.39%)
IBB : 132.73 (+1.16%)
SLXN : 2.44 (+0.83%)
SPY : 591.15 (+1.20%)
XBI : 91.28 (+1.64%)
ZIM : 18.29 (-0.49%)
Trump Names Anti-Vaxxer Robert Kennedy As Health & Human Services Secretary: Here’s What It Means For Healthcare Stocks

Trump said his HHS Secretary nominee will ensure the public is protected from harmful substances that have aggravated the nation’s health crisis.

NVO : 85.00 (-17.83%)
IBB : 132.73 (+1.16%)
LLY : 767.76 (+1.35%)
MRNA : 39.39 (-0.43%)
AMGN : 263.38 (+0.84%)
XBI : 91.28 (+1.64%)
PFE : 26.36 (+2.29%)
BNTX : 113.08 (+1.56%)
SNY : 47.71 (+0.44%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Average short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Fund Summary

The iShares Nasdaq Biotechnology ETF seeks to track the investment results of an index composed of biotechnology and pharmaceutical equities listed on the NASDAQ. The Fund seeks investment results that correspond generally to the price and yield performance, before fees and expenses, of the NASDAQ Biotechnology...

See More

Key Turning Points

3rd Resistance Point 137.84
2nd Resistance Point 135.93
1st Resistance Point 134.33
Last Price 132.73
1st Support Level 130.82
2nd Support Level 128.91
3rd Support Level 127.31

See More

52-Week High 150.57
Fibonacci 61.8% 140.26
Fibonacci 50% 137.08
Fibonacci 38.2% 133.90
Last Price 132.73
52-Week Low 123.60

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar